Boston Biomedical Innovation Center (B-BIC) is a life sciences accelerator funded by the National Institutes of Health and our member institutions to increase the return on investment in research. We speed the translation of research technologies into products for doctors and their patients, for the good of society.
Our members are a consortium of academic medical centers in Boston including Brigham and Women’s Hospital, Harvard Medical School, Massachusetts General Hospital, and the Massachusetts Institute of Technology.
B-BIC provides funding for technology development and translational research, including regulatory, reimbursement, and business development aspects that are part of an overall commercialization strategy.
TITLE: Novel Small Molecule Therapeutics for Genetic Lung and Blood Diseases TYPE OF AWARD: Drive CLINICAL AREA: Small Molecule INSTITUTION: Boston Children’s Hospital DESCRIPTION: Telomere diseases encompass a spectrum of rare and fatal syndromes that are caused by mutations in genes regulating telomere biology. These include the severe childhood blood disorder dyskeratosis congenita (DC) and later-onset diseases such as…Read More
TITLE: NEDD9 Monoclonal Antibody Therapeutic for Pulmonary Thromboembolic Disease TYPE OF AWARD: Drive CLINICAL AREA: Biologic INSTITUTION: Brigham and Women’s Hospital DESCRIPTION: Increased platelet-endothelial adhesion is a central pathobiological event underlying the pathogenesis of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Current therapies to treat thrombosis in PAH and CTEPH emphasize non-specific coagulation proteins, and are associated…Read More
Contributed by Ilsa Webeck B-BIC Skills Development Expert Developing Innovative Strategies for Leading Edge Medical Technology Companies “I have an idea. A great idea. I mean, it’s an “I can’t believe no one has thought of this before” idea. The market for this product is going to be enormous.” In conversations with innovators spanning devices, biologics,…Read More
Written by Paul Tessier A common refrain heard by healthcare entrepreneurs is that they should focus on satisfying an “unmet clinical need,” however there is no universal definition of the phrase, “unmet clinical need.” Even established companies and public healthcare agencies, who use the concept of an unmet clinical need to assist in developing product…Read More
We are thrilled to share with you a new web video we are releasing that highlights our ‘Commercialization Coaches’ and other services that are ways B-BIC successfully differentiates from other grants. Kantum Pharma, dedicated to the prevention and treatment of Acute Kidney Injury, received its first B-BIC Pilot grant in 2017.Read More
Technology in Search of an Application Part II of the Specialist Series: The Road to Commercialization: Challenges and Opportunities Written by John Randle Development models always start with addressing clinical needs, but scientific discoveries and technological advances typically happen independently from solving clinical problems. This article will explore ways you can ensure that you are…Read More
Q: Do I need to have slides? A: Pitches only need to address the suggested elements. Use of reference materials or other visual elements is welcome if they help convey the product concept and can be shared using your laptop screen. AV equipment will not be available. Q: How formal will the pitches be? A:…Read More
Keep pitch short and focused on the technology and its commercial application. Limit the discussion of preliminary results, and focus on the most relevant results with conclusions – not data. Present the science within the context of the business strategy. This event will provide you with the opportunity to pitch a team of experts on your research.…Read More
Written by Erin McKenna, B-BIC Deputy Director There are multiple frameworks out there that outline the process for developing promising biomedical research into a range of innovative solutions – pharmaceuticals, biologics, medical devices, and diagnostics. Many of these processes leverage concepts that come from regulations developed by the FDA, the European Commission and others to…Read More
TITLE: Generation of a Novel Therapeutic Antibody for Treatment of Allergic Asthma TYPE OF AWARD: Pilot CLINICAL AREA: Lung INSTITUTION: Brigham and Women’s Hospital DESCRIPTION: Asthma affects 8% of the US population, approximately 25 million people. About 10% of patients have severe asthma, accounting for an estimated 1.8 million emergency department visits, 439,000 hospitalizations, and 3,630 deaths annually…Read More
Over the course of 2019, our coaches and staff broke down the B-BIC application process to provide you with expert advice on all the of the questions we ask you to answer when applying for our program. For those who are not applying yet, the B-BIC proposal has many similarities to a business plan, which…Read More
TITLE: Diagnostic for Acute Kidney Injury Associated with Cardiovascular Diseases TYPE OF AWARD: Drive TECHNOLOGY TYPE: Diagnostic INSTITUTION: MGH DESCRIPTION: Acute kidney injury (AKI) is a frequent complication in hospitalized patients, including those undergoing cardiac surgery. However, two critical barriers to the clinical management of these critically ill patients remain the need for better methods…Read More
TITLE: A Rapid, Inexpensive Platelet Function Test TYPE OF AWARD: Pilot CLINICAL AREA: Blood INSTITUTION: BIDMC DESCRIPTION: Antiplatelet agents such as clopidogrel and aspirin are used in the treatment of heart attacks and strokes and are among the most commonly used drugs in the U.S. Problems associated with these drugs include bleeding risk (which complicates invasive…Read More
By Jay Knowles Partner, Innovation Many venture capitalists look for opportunities to invest in a company or a project such that if it reaches a certain inflection point, that company will become significantly more valuable, and what it will cost to get it to that point. As an example, investors often like to see how…Read More
Written by Carl Berke, PhD. Partner at the Partners Innovation Fund Thomas Edison famously remarked, “Invention is 1% inspiration and 99% perspiration”. The Wizard of Menlo Park was a prolific inventor who never left his lab, but his intellectual property was adopted by a plethora of companies who translated his technology into products that delighted…Read More